Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine

Vaccine

Volumn 16, Issue 2-3, 1998, Pages 216-224

  Yoo, Yung Choon ^a   Yoshimatsu, Kumiko ^a   Koike, Yuko ^a   Hatsuse, Rei ^a   Yamanishi, Koichi ^b   Tanishita, Osamu ^c   Arikawa, Jiro ^a   Azuma, Ichiro ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c The Research Foundation for Microbial Diseases of Osaka University   (Japan)

Author keywords

Adjuvant; Hantaan virus; Muramyl dipeptide; Vaccine efficacy

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; MURAMYL DIPEPTIDE; MURAMYL DIPEPTIDE DERIVATIVE; NEUTRALIZING ANTIBODY;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HANTAVIRUS; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; FEMALE; HANTAVIRUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES;

EID: 0031986108     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00188-6     Document Type: Article

References (42)

1. 1 Adam, A., Devys, M., Souvannavong, V., Lefrancier, P., Choay, J. and Lederer, E. Correction of structure and adjuvant activity of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogs. Antiadjuvant and competition properties of stereoisomers. Biochem. Biophys. Res, Commun. 1976, 72, 336-346.
2. 2 Adam, A., Ciorbaru, R., Ellouz, F., Petit, J.F. and Lederer, E. Adjuvant activity of monomeric bacterial cell wall peptidoglycans. Biochem. Biophys. Res. Commun. 1974, 56, 561-567.
3. 3 Ellouz, F., Adam, A., Ciorbaru, R. and Lederer, E. Minimal structure requirement for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 1974, 59, 1317-1325.
4. 4 Azuma, I., Kamisango, K., Saiki, I., Tanio, Y., Kobayashi, S. and Yamamura, Y. Adjuvant activity of Nacetyl muramyl dipeptides for the induction delayedtype hypersensitivity to azobenzine-arsonate-N-acetyl-L-tyrosine in guinea pig2E Infect. Immun. 1980, 29, 1193-1196.
5. 5 Azuma, I. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine 1992, 10, 1000-1006.
6. 6 Ishihara, C., Iida, J. and Mizukoshi, N. et al. Effect of Nα-acetyl-muramyl-L-alanyl-D-isoglutaminyl-Nα-stearoyl-L-lysine on resistance to herpes simplex virus type1 infection in cyclophosphamide treated mice. Vaccine 1989, 7, 309-313.
7. 7 Ishihara, C., Mizukoshi, N., Iida, J., Yamamoto, K. and Azuma, I. Suppression of Sendai virus growth by treatment of Nα-acetyl-muramyl-L-alanyl-D-isoglutaminyl-Nα-stearoyl-L-lysine in mice. Vaccine 1987, 5, 295-301.
8. γ-stearoyl lysine. Infect. Immun. 1983, 39, 1029-1040.
9. 9 Ishihara, C., Hamada, N., Yamamoto, K., Iida, J., Azuma, I. and Yamamura, Y. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice. Vaccine 1985, 3, 370-374.
10. 10 Saiki, I., Saito, S. and Fujita, C. et al. Induction of tumoricidal macrophages and production of cytokines by synthetic muramyl dipeptide analogs. Vaccine 1988, 6, 238-244.
11. 11 Yamaguchi, F., Akasaki, M. and Tsukada, W. Induction of colonystimulating factor and stimulation of stem cell proliferation by injection of muroctasin. Arzneim. Forsch./Drug Res. 1988, 38, 980-984.
12. 12 Yoo, Y.C., Saiki, I., Sato, K. and Azuma, I. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumors in mice. Vaccine 1994, 12, 175-180.
13. 13 Yoo, Y.C., Yoshimatsu, K., Hatsuse, R., Tamura, M., Yoshida, R., Tono-Oka, S., Arikawa, J. and Azuma, I. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus in newborn mice. Vaccine 1995, 13, 1300-1305.
14. 14 Yoo, Y.C., Saiki, I., Sato, K. and Azuma, I. B30-MDP, a synthetic muramyl depitide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice. Vaccine 1992, 10, 792-797.
15. 15 Casals, J., Hoogstraal, H., Johnson, K.M., Shelokov, A., Wiebenga, N.H. and Work, T.H. A current appraisal of hemorrhagic fever in the USSR. Am. J. Trop. Med. Hyg. 1966, 15, 751-764.
16. 16 Lee, H.W. Korean hemorrhagic fever. Prof. Med. Virol. 1982, 28, 96-113.
17. 17 World Health Organization Hemorrhagic fever with renal syndrome: memorandum from a WHO meeting. Bull. WHO 1983, 61, 269-275.
18. 18 Schmaljohn, C.S., Hasty, S.E., Harrison, S.A. and Dalrymple, J.M. Characterization of Hantaan virus virions, the prototype virus of hemorrhagic fever with renal syndrome. J. Infect. Dis. 1983, 148, 1005-1012.
19. 19 Lee, H.W., Lee, P.W. and Johnson, K.M. Isolation of the etiologic agent of Korean hemorrhagic fever. J. Infect. Dis. 1987, 137, 298-308.
20. 20 Gupta, R.K., Relyveld, E.H., Lindblad, B.E., Bizzini, B., Ben-Efraim, S. and Gupta, C.K. Adjuvants - a balance between toxicity and adjuvancity. Vaccine 1993, 11, 293-306.
21. 21 Veien, N.K., Hattel, T., Justesen, O. and Norholm, A. Aluminium allergy. Contact Dermatitis 1986, 15, 295-297.
22. 22 Nagel, J., Svec, D., Waters, T. and Fireman, P. IgE synthesis in man: I. Development of specific IgE antibodies after immunization with tetanus-diphtheria (Td) toxoids. J. lmmunol. 1977, 118, 334-341.
23. 23 Tamura, M., Yoo, Y.C., Yoshimatsu, K., Yoshida, R., Oka, T., Ohkuma, K., Arikawa, J. and Azuma, I. Effect of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen. Vaccine 1995, 13, 77-82.
24. 24 Lee, H.W., Lee, P.W. and Johnson, K.M. Isolation of the etiologic agent of Koream hemorrhagic fever. J. Infect. Dis. 1978, 137, 298-308.
25. 25 Kitamura, T., Morita, C., Komatsu, T., Sugiyama, K., Arikawa, J., Shiga, K., Takara, H., Akao, Y., Imaizumi, K., Oya, A., Hashimoto, N. and Urasawa, S. Isolation of virus causing hemorrhagic fever with renal syndrome (HFRS) through a cell culture system. Jpn. J. Med. Sci. Biol. 1983, 36, 17-25.
26. 26 Yoo, Y.C., Yoshimatsu, K., Yoshida, R., Tamura, M., Azuma, I. and Arikawa, J. Comparsion of virulence between Seoul virus strain SR-11 and Hantaan virus strain 76-118 of Hantaviruses in newborn mice. Microbiol. Immunol. 1993, 37, 557-562.
27. 27 Yamanishi, K., Dantas, J.R. Jr, Takahashi, M., Yamanouchi, T., Domae, T., Kawamata, J. and Kurata, T. Isolation of hemorrhagic fever with renal syndrome (HFRS) virus from a tumor sepcimen in a rat. Biken J. 1983, 26, 155-160.
28. 28 Yamanishi, K., Tanishita, O., Tamura, M., Asada, H., Kondo, K., Takagi, M., Yoshida, I., Konobe, T. and Fukai, K. Development of inactivated vaccine against virus causing hemorrhagic fever with renal syndrome. Vaccine 1988, 6, 278-282.
29. 29 Xu-Amano, J., Jackson, R.J., Fujihashi, K., Kiyono, H., Staats, H.F. and McGhee, J.R. Helper Th-1 and Th-2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine 1994, 12, 903-911.
30. 30 Yoshimatsu, K., Yoo, Y.C., Yoshida, R., Ishihara, C., Azuma, I. and Arikawa, J. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirusexpressed proteins. Arch. Virol. 1993, 130, 365-376.
31. 31 Melamed, D. and Friedman, A. Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur. J. Immunol. 1993, 23, 935-942.
32. 32 Audibert, F.M. and Lise, L.D. Adjuvants: current status, clinical perspectives and future prospects, Immunol. Today 1993, 14, 281-284.
33. 33 Lovgren, K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostaining complexes. Scand. J. Immunol. 1988, 27, 241-245.
34. 34 Pyle, S.W., Morein, B., Bess, J.W. Jr, Akerblom, L., Nara, P.L. and Nigida, S.M. Jr et al. Immune response to immunostimulatory complexes (ISCOMS) prepared from human immunodeficiency virus type 1 (HIV-1) or HIV-1 external envelope glycoprotein (gp120). Vaccine 1989, 7, 465-473.
35. 35 Byars, N.E., Allison, A.C., Harmon, M.W. and Kendal, A.P. Enhancement of antibody response to influenza B virus haemagglutinin by use of a new adjuvant formulation. Vaccine 1990, 8, 49-56.
36. 36 Byars, N.E., Nakano, G., Welch, M., Lehman, D. and Allison, A.C Improvement of hepatitis B vaccine by the use of a new adjuvant. Vaccine 1991, 9, 309-318.
37. 37 Haigwood, N.L., Nara, P.L., Brooks, E., Van Nest, G.A., Ott, G. and Higgins, K.W. et al. Native but not denatured recombinant human immunodefficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 1992, 66, 172-182.
38. 38 Arikawa, J., Schmaljohn, A.L., Dalrymple, J.M. and Schmaljohn, C.S. Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies. J. Gen. Virol. 1989, 70, 615-624.
39. 39 Powrie, F. and Coffman, R.L. Cytokine regulation of T-cell function: potential for therapeutic intervention, Immunol. Today 1993, 14, 270-274.
40. 40 Ahmed, R., Salmi, A., Butler, L.D., Chiller, J.M. and Oldstone, M.B.A. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. J. Exp. Med. 1984, 60, 521-540.
41. 41 Asada, H., Tamura, M., Kondo, K., Okuni, Y., Takahashi, Y., Dohi, Y., Nagai, T., Kurata, T. and Yamanashi, K. Role of T lymphocyte subsets in protection and recovery from Hantaan virus infection in mice. J. Gen. Virol. 1987, 68, 1961-1969.
42. 42 Tamura, M., Asada, H., Kondo, K., Tanishita, O., Kurata, T. and Yamanishi, K. Pathogenesis of Hantaan virus in mice. J. Gen. Virol. 1989, 70, 2897-2906.